prostate cancer	is a	malignant tumor of the prostate
prostate cancer	originates in	prostate gland
prostate cancer	is a type of	cancer
prostate cancer	commonly associated with	age
prostate cancer	associated with	BRCA2 mutation
prostate cancer	associated with	African descent
family history	increases risk for	prostate cancer
BRCA2 mutation	increases risk for	prostate cancer
age	increases risk for	prostate cancer
African descent	increases risk for	prostate cancer
PSA testing	used for	screening of prostate cancer
digital rectal exam	used for	screening of prostate cancer
Gleason score	informs	prognosis of prostate cancer
Gleason score	correlates with	tumor aggressiveness
PSA level	correlates with	tumor burden
biopsy	confirms	prostate cancer
MRI	used for	staging of prostate cancer
CT scan	used for	staging of prostate cancer
bone scan	used for	detection of metastasis
PSMA PET	used for	staging of prostate cancer
radical prostatectomy	indicated for	localized prostate cancer
radical prostatectomy	may cause	urinary incontinence
radical prostatectomy	may cause	erectile dysfunction
brachytherapy	indicated for	localized prostate cancer
external beam radiotherapy	indicated for	localized prostate cancer
androgen deprivation therapy	used for	metastatic prostate cancer
ADT	used for	castration-sensitive prostate cancer
docetaxel	approved for	metastatic castration-resistant prostate cancer
cabazitaxel	approved for	metastatic castration-resistant prostate cancer
abiraterone	approved for	metastatic castration-resistant prostate cancer
enzalutamide	approved for	metastatic castration-resistant prostate cancer
apalutamide	approved for	nonmetastatic castration-resistant prostate cancer
radium-223	approved for	metastatic castration-resistant prostate cancer with bone metastases
Lutetium-177-PSMA	used for	metastatic castration-resistant prostate cancer
sipuleucel-T	used for	metastatic castration-resistant prostate cancer
prostate cancer	metastasizes to	bone
prostate cancer	metastasizes to	liver
prostate cancer	metastasizes to	lung
prostate cancer	metastasizes to	lymph nodes
bone metastasis	causes	bone pain
bone metastasis	leads to	pathologic fracture
bone metastasis	contributes to	skeletal-related events
bone pain	indicates	bone metastasis
urinary incontinence	results from	radical prostatectomy
erectile dysfunction	results from	radical prostatectomy
erectile dysfunction	results from	radiation therapy
urinary incontinence	may persist after	radiotherapy
PSA	used for	monitoring of disease activity
disease activity	monitored by	PSA
clinical stage	determines	treatment plan
staging	guides	treatment decisions
Gleason score	stratifies	prognosis categories
Gleason score	guides	treatment intensity
tumor stage	determines	regional spread
lymph node metastasis	indicates	advanced disease
node-negative status	indicates	localized disease
node-positive status	indicates	metastatic disease
bone metastasis	is common site	for prostate cancer
bone metastasis	causes	skeletal-related events
disease progression	leads to	mortality
mortality	associated with	age at diagnosis
mortality	influenced by	Gleason score
comorbidity	affects	treatment choice
age	guides	treatment selection
urinary tract obstruction	caused by	tumor growth
urinary obstruction	common in	advanced prostate cancer
bone density loss	caused by	androgen deprivation therapy
cardiovascular risk	increased by	androgen deprivation therapy
bone health	protected by	denosumab therapy
denosumab	used for	prevention of skeletal-related events
PSA doubling time	predicts	progression risk
PSA velocity	correlates with	treatment response
imaging	guides	staging of prostate cancer
staging	stratifies	prognosis
prostate cancer	prognosis poorer with	metastatic disease
castration-resistant prostate cancer	arises from	prostate cancer progression
testosterone	suppression by	androgen deprivation therapy
androgen receptor signaling	drives	prostate cancer progression
PSMA expression	increases with	disease progression
axial skeleton	affected by	bone metastases
pelvic bones	involved in	metastasis
surgical margins	influence	recurrence risk
negative surgical margin	indicates	complete resection
positive surgical margin	indicates	residual disease
active surveillance	appropriate for	low-risk prostate cancer
watchful waiting	appropriate for	elderly patients with prostate cancer
recurrence	occurs after	primary therapy for prostate cancer
adjuvant therapy	used for	post-surgical prostate cancer
neoadjuvant therapy	used for	localized prostate cancer
focal therapy	used for	selected localized prostate cancers
hormone-sensitive prostate cancer	responds to	androgen deprivation therapy
castration-resistant prostate cancer	progresses despite	castration levels of testosterone
testosterone	suppression by	androgen deprivation therapy
androgen receptor signaling	drives	prostate cancer progression
PSMA expression	increases with	disease progression
bone metastasis	imaging with	bone scan
bone metastasis	alters	mobility
disease-free survival	defined as	absence of recurrence
overall survival	improved by	docetaxel
progression-free survival	improved by	abiraterone
quality of life	affected by	treatment side effects
palliative care	improves	quality of life
urinary symptoms	worsen with	disease progression
erectile function	affected by	prostate cancer treatment
sexual health	affected by	prostate cancer treatment
family history	informs	genetic testing decision
genetic testing	informs	risk assessment for relatives
BRCA2 status	influences	treatment choice
genetic mutation	predisposes to	prostate cancer
prostate cancer	may cause	anemia
anemia	worsens	fatigue
fatigue	accompanies	cancer treatment
bone scan	screens for	bone metastases
bone metastasis	worsens	mobility
recurrence	occurs after	primary therapy for prostate cancer
adjuvant therapy	used for	post-surgical prostate cancer
neoadjuvant therapy	used for	localized prostate cancer
focal therapy	used for	selected localized prostate cancers
hormone-sensitive prostate cancer	responds to	androgen deprivation therapy
castration-resistant prostate cancer	progresses despite	castration levels of testosterone
testosterone	remains at	castration levels after therapy
PSMA PET imaging	detects	metastases
PSA nadir	associated with	response to therapy
partial response	indicates	tumor shrinkage
complete response	indicates	no measurable disease
palliative care	improves	quality of life
quality of life	affected by	treatment side effects
bone-targeted therapy	reduces risk of	skeletal-related events in bone metastases
